COPENHAGEN, Denmark, March 12, 2018 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win ...

IO Biotech (NASDAQ:IOBT) has filed for the sale of up to 5.6M shares of common stock for holders. Filing More on IO Biotech IO Biotech GAAP EPS of -$0.34 beats by $0.11 Seeking Alpha’s Quant Rating on ...

IO Biotech Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA ® (pembrolizumab) in ...

(RTTNews) - Shares of IO Biotech, Inc. (IOBT) are up more than 21% on Friday at $10.05. There have been no company-specific news reported that could drive the stock up. The Denmark based clinical ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck and Merck is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. IO Biotech ...